Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director comp.
Quarterly results
Inv. presentation
Asset disposition
|
|
RAPT Therapeutics, Inc. (RAPT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
8-K
| Quarterly results|
Docs:
|
"RAPT Therapeutics Reports First Quarter 2023 Financial Results Company maintains strong cash position of $231.6 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the first quarter ended March 31, 2023. “In 2023, we are continuing to focus on advancing our two lead programs, RPT193 and FLX475,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “In the first quarter, we expanded our RPT193 program with the initiation of a Phase 2a clinical trial in asthma. We co..." |
|
| 03/14/2023 |
8-K
| Investor presentation, Quarterly results|
Docs:
|
"RAPT Therapeutics Reports Fourth Quarter And Year End Financial Results Company maintains strong cash position of $249.1 million SOUTH SAN FRANCISCO, Calif. – – RAPT Therapeutics, Inc. , a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the fourth quarter and year ended December 31, 2022. “2022 was an important year of progress, as we advanced both of our two lead programs, RPT193 and FLX475, in inflammatory disease and cancer, respectively,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “This progress has positioned us ...",
"29 8 15 43" |
|
| 11/10/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 03/10/2022 |
8-K
| Quarterly results |
| 11/10/2021 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"RAPT Therapeutics Reports Third Quarter 2021 Financial Results SOUTH SAN FRANCISCO, Calif. - November 10, 2021 - RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the third quarter and nine months ended September 30, 2021. “This has been an important year for RAPT as we advance the development of RPT193 in atopic dermatitis and FLX475 in cancer,” said Brian Wong, M.D., Ph.D., President and Chief Executive Officer of RAPT Therapeutics. “In the third quarter, we presented additional incremental data for RPT193 at two separate dermatology meetings, allowing..." |
|
| 05/11/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
8-K
| Quarterly results |
| 11/16/2020 |
8-K
| Quarterly results|
Docs:
|
"RAPT Therapeutics Reports Third Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. - November 16, 2020 - RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent operational and business progress. “Earlier today, we reported positive initial data from our ongoing Phase 1/2 clinical trial evaluating FLX475 in multiple cancer indications,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “With the advancement of this program and continued enrollment for our on...",
"RAPT Therapeutics Reports Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of FLX475 in Multiple Cancer Indications",
"RAPT Therapeutics, Inc. Investor Presentation" |
|
| 08/14/2020 |
8-K
| Quarterly results |
| 05/14/2020 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : May 14, 2020 RAPT Therapeutics, Inc. Delaware 001-38997 47-3313701 561 Eccles Avenue South San Francisco, CA 94080 489-9000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e-4 un...",
"RAPT Therapeutics Reports First Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif. - May 14, 2020 - RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2020 and provided an update on recent operational and business progress. “We continue to progress our programs during these challenging times. Our first priority is to protect our employees and our patients. We are practicing social distancing in the lab and conducting a good portion of our work remotely,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Ther..." |
|
| 03/30/2020 |
8-K
| Quarterly results |
| 12/11/2019 |
8-K
| Quarterly results|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 of the Securities Exchange Act of 1934 Date of Report : December 11, 2019 RAPT Therapeutics, Inc. Delaware 001-38997 47-3313701 561 Eccles Avenue South San Francisco, CA 94080 489-9000 Not Applicable Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions : ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communications pursuant to Rule 13e...",
"RAPT Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights SOUTH SAN FRANCISCO, Calif. - December 11, 2019 - RAPT Therapeutics, Inc. , a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2019 and provided an update on recent operational and business progress. “We are pleased to report significant progress as a public company following our initial public offering,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “This includes clinical and operational advancement of our two lead compounds, FLX475 f..." |
|
|
|